Date
Changes to Preferred Biosimilar Medications Effective October 1, 2026
Beginning October 1, 2026, MO HealthNet will change the preferred product for several biologic agents. These updates support access to high-quality, clinically effective treatments and help manage program costs responsibly. The affected biologic agents are listed below. Changes from current management appear in bold and italics.
- Infliximab
- Preferred agents
- Inflectra
- Infliximab
- Non-Preferred agents
- Avsola
- Idacio
- Remicade
- Renflexis
- Zymfentra
- Preferred agents
- Adalimumab
- Preferred agents
- Adalimumab-adaz (gen Hyrimoz)
- Hadlima
- Non-Preferred agents
- Abrilada
- Adalimumab-aacf (gen Idacio)
- Adalimumab-aaty (gen Yuflyma)
- Adalimumab-adbm (gen Cyltezo)
- Adalimumab-ryvk (gen Simlandi)
- Amjevita
- Cyltezo
- Hulio
- Humira
- Hyrimoz
- Idacio
- Simlandi
- Yuflyma
- Yusimry
- Preferred agents
- Ustekinumab
- Preferred agents
- Pyzchiva
- Non-Preferred agents
- Imuldosa
- Otulfi
- Selarsdi
- Starjemza
- Stelara
- Steqeyma
- Ustekinumab
- Yesintek
- Preferred agents
What this means for your practice:
Prescribers, clinical staff, and pharmacy providers are encouraged to review active participant regimens well ahead of the October 1 effective date to prepare for this transition.
- Existing Prior Authorizations (PAs): For participants currently receiving a biologic agent that becomes non-preferred on October 1, current clinical PA approvals for that active biologic ingredient will remain valid. A new clinical prior authorization is not required.
- Mandatory Product Switching: Clinical authorization will remain valid; however, participants must switch to a preferred version of the biologic ingredient on or after October 1, unless an override for the Biosimilar vs. Reference Product Fiscal Edit is explicitly approved. The current listing of preferred and non-preferred biologic agents in the Biosimilar vs. Reference Product Fiscal Edit is available at Pharmacy Clinical Edits and Preferred Drug Lists | mydss.mo.gov.